Table III.

Summarized results for the studies with “clinical benefit” and “overall response” as outcome

Study	Δ Clinical benefit in 100 patients	Δ Overall response in 100 patients	Δ Cost (USD) in 100 patients		ICER Cost per one more OR in 100 patients		Consideration based on comparing ICER with threshold
			Generic	Brand	Generic	Brand	Brand	Generic
Paridaens et al., 2008 [27] (EXE-TAM)	NR	14.4	31800	62300	2208	4326	HCE	HCE
Campos et al., 2009 [25] (EXE-ANA)	N sig	N sig	NAv in Iran	46100	NA	NA	NA	Dominated
Kaufmann et al. 2000 [26] (EXE-MA)	N sig	N sig	18600	NAv in Iran	NA	NA	Dominated	Dominated

OR – overall response, N sig – not significant, NA – not applicable, NAv – not available, USD – United States dollar, HCE – highly cost effective, ICER – incremental cost-effectiveness ratio